Northwest Biotherapeutics (NASDAQ: NWBO) confirmed that its Phase III trial of DCVax-L for newly diagnosed glioblastoma multiforme (GBM) is ongoing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE